Skip to content

The effect of Tongfu Tiaoshen acupuncture on cognitive impairment after stroke: A randomized controlled trial

The effect of Tongfu Tiaoshen acupuncture on cognitive impairment after stroke: A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001095
Enrollment
Unknown
Registered
2025-06-03
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment after stroke

Interventions

Sham acupuncture group:Sham-acupuncture was performed on the basis of stroke routine and 10 non-acupuncture points were acupuncture
Acupuncture group:Acupuncture points Baihui Sishencong Shenting Shenmen Neiguan Tianshu Zusanli Shangjuxu Xiagjuxu and Sanyinjiao were needled.

Sponsors

Rongjun Hospital of Hubei Provincial
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The subject meets the diagnostic criteria for ischemic or hemorrhagic stroke and at the same time is diagnosed with post-stroke cognitive impairment (Expert Consensus on the Management of Post-stroke Cognitive Impairment (2021)) 2.Patients with neuroimaging-confirmed stroke; 3.According to the Expert Consensus on the Management of Cognitive Impairment after Stroke (2021) the Montreal Cognitive Assessment Scale (MoCA) <26;State Test (MMSE): MMSE score < 17 (illiterate) or MMSE score < 20 (primary school literacy) or MMSE score < 24 (secondary school and above); 4.Men and women between the ages of 30 and 70 years; 5.The patient signed the informed consent form to cooperate with the treatment;

Exclusion criteria

Exclusion criteria: 1.Have Alzheimer's disease Parkinson's disease frontotemporal dementia Huntington's disease demyelinating disease post-traumatic cognitive impairment or diseases such as central nervous system infections; 2.Previous medical conditions such as epilepsy psychosis or brain tumors; 3.Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal or severe liver disease; 4.Glomerular filtration rate <30mL/min/1.72m2 or severe renal disease; 5.Severe visual or hearing impairment severe aphasia that may affect the assessment;

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MOCA);

Secondary

MeasureTime frame
Mini-Mental State Examination (MMSE);Lovington Homework Therapy Cognitive Assessment Kit (LOTCA);Activities of Daily Living Scale (ADL);fNIRS brain function measurement;

Countries

china

Contacts

Public ContactZHANGzheng-xing

Rongjun Hospital of Hubei Provincial

786817798@qq.com18071071039

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026